Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 31:14:213.
doi: 10.3389/fnins.2020.00213. eCollection 2020.

Neurodegenerative Diseases - Is Metabolic Deficiency the Root Cause?

Affiliations
Review

Neurodegenerative Diseases - Is Metabolic Deficiency the Root Cause?

Vignayanandam Ravindernath Muddapu et al. Front Neurosci. .

Abstract

Neurodegenerative diseases, including Alzheimer, Parkinson, Huntington, and amyotrophic lateral sclerosis, are a prominent class of neurological diseases currently without a cure. They are characterized by an inexorable loss of a specific type of neurons. The selective vulnerability of specific neuronal clusters (typically a subcortical cluster) in the early stages, followed by the spread of the disease to higher cortical areas, is a typical pattern of disease progression. Neurodegenerative diseases share a range of molecular and cellular pathologies, including protein aggregation, mitochondrial dysfunction, glutamate toxicity, calcium load, proteolytic stress, oxidative stress, neuroinflammation, and aging, which contribute to neuronal death. Efforts to treat these diseases are often limited by the fact that they tend to address any one of the above pathological changes while ignoring others. Lack of clarity regarding a possible root cause that underlies all the above pathologies poses a significant challenge. In search of an integrative theory for neurodegenerative pathology, we hypothesize that metabolic deficiency in certain vulnerable neuronal clusters is the common underlying thread that links many dimensions of the disease. The current review aims to present an outline of such an integrative theory. We present a new perspective of neurodegenerative diseases as metabolic disorders at molecular, cellular, and systems levels. This helps to understand a common underlying mechanism of the many facets of the disease and may lead to more promising disease-modifying therapeutic interventions. Here, we briefly discuss the selective metabolic vulnerability of specific neuronal clusters and also the involvement of glia and vascular dysfunctions. Any failure in satisfaction of the metabolic demand by the neurons triggers a chain of events that precipitate various manifestations of neurodegenerative pathology.

Keywords: excitotoxicity; glia-vascular integrity; insulin resistance; metabolic deficiency; mitochondrial dysfunction; oxidative stress; protein mishandling; selective vulnerability.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Selective vulnerable neuronal population in various neurodegenerative disorders. STR, striatum; SNc, substantia nigra pars compacta; CA1, cornu ammonis 1; MN, motor neuron; FF, fast fatigable.
FIGURE 2
FIGURE 2
Glutamate-induced excitotoxicity in various neurodegenerative disorders. SNc, substantia nigra pars compacta; STN, subthalamic nucleus; DA, dopamine; GLU, glutamate; CA1, cornu ammonis 1; CA3, cornu ammonis 3; HC, hippocampus; MSN, medium spiny neuron; PYR, pyramidal neuron; BG, basal ganglia; FF MN, fast fatigable motor neuron; SC, spinal cord.
FIGURE 3
FIGURE 3
The plausible hypothesis for selective neurodegeneration in various neurodegenerative disorders. EAAR, excitatory amino acid receptors; MCU, mitochondrial calcium uniporter; SERCA, sarcoplasmic/endoplasmic reticulum Ca2+-ATPase; EAAT, excitatory amino acid transporters; CBF, cerebral blood flow; Ca2+, calcium; ATP, adenosine triphosphate; ROS, reactive oxygen species. BBB, blood-brain barrier; Cytc, cytochrome c; MTP, mitochondrial transition pore; NMDA, N-methyl-D-aspartate; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; VGLUT, vesicular glutamate transporter.

References

    1. Abbott N. J. (2002). Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 200 629–638. 10.1046/j.1469-7580.2002.00064.x - DOI - PMC - PubMed
    1. Adami P. V. M., Quijano C., Magnani N., Galeano P., Evelson P., Cassina A., et al. (2017). Synaptosomal bioenergetic defects are associated with cognitive impairment in a transgenic rat model of early Alzheimer’s disease. J. Cereb. Blood Flow Metab. 37 69–84. 10.1177/0271678X15615132 - DOI - PMC - PubMed
    1. Ahmed R. M., Irish M., Piguet O., Halliday G. M., Ittner L. M., Farooqi S., et al. (2016). Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. Lancet Neurol. 15 332–342. 10.1016/S1474-4422(15)00380-4 - DOI - PubMed
    1. Akila Parvathy, Dharshini S., Taguchi Y., Michael Gromiha M. (2019). Exploring the selective vulnerability in Alzheimer disease using tissue specific variant analysis. Genomics 111 936–949. 10.1016/j.ygeno.2018.05.024 - DOI - PubMed
    1. Albin R. L., Greenamyre J. T. (1992). Alternative excitotoxic hypotheses. Neurology 42 733–738. 10.1212/WNL.42.4.733 - DOI - PubMed

LinkOut - more resources